Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
Open Access
- 12 June 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12), 4197
- https://doi.org/10.3390/ijms21124197
Abstract
Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.Funding Information
- Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
This publication has 306 references indexed in Scilit:
- Assessment of Tropism and Effectiveness of New Primate-Derived Hybrid Recombinant AAV Serotypes in the Mouse and Primate RetinaPLOS ONE, 2013
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsJAMA Ophthalmology, 2012
- Fluorescence-based evaluation of shRNA efficacyAnalytical Biochemistry, 2011
- AAV Mediated GDNF Secretion From Retinal Glia Slows Down Retinal Degeneration in a Rat Model of Retinitis PigmentosaMolecular Therapy, 2011
- Restoration of Cone Vision in the CNGA3−/− Mouse Model of Congenital Complete Lack of Cone Photoreceptor FunctionMolecular Therapy, 2010
- Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injectionExperimental Eye Research, 2010
- Induction of Rapid and Highly Efficient Expression of the Human ND4 Complex I Subunit in the Mouse Visual System by Self-complementary Adeno-Associated VirusJAMA Ophthalmology, 2010
- Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutationsGene Therapy, 2009
- Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapyGene Therapy, 2008
- Targeting gene expression to cones with human cone opsin promoters in recombinant AAVGene Therapy, 2008